PDCD1 and Miyoshi myopathy: The results of a clinical trial showed that the combination of Indoximod and the anti-PD-1 antibody Pembrolizumab in advanced MM patients had a PR of 61%, a median PFS of 12.9 months, and a 1-year survival rate of 56%, suggesting that Indoximod and Pembrolizumab have a significant synergistic anti-tumor effect [92].